Lung Cancer Diagnostics Post COVID
- a Multidisciplinary View

August 26, 2020, 90min
Various diagnostic tools play indispensable roles in diagnosing, staging, treatment selection & monitoring of lung cancer patients. In this webinar Dr James Ho, University of Hong Kong, Dr Anand Sachithanandan, Sunway Medical Center Malaysia and Dr Takayuki Takahama,Kindai University Hospital Japanshare multidisciplinary perspectives on 1) how diagnostics algorithms including biomarkers and other testing modalities influence decisions on targeted therapy selection; 2) how COVID has impacted management of oncology patients.

Connecting Oncology and Pathology in the personalized care of NSCLC patients

November 13, 2020, 58min
Lung cancer remains one of the most difficult-to-treat cancers. Treatment landscape of NSCLC has been evolving dramatically in the past ten years, and biomarker testing is becoming increasingly complex. Discussion between oncologists and pathologists plays an integral role in biomarker-driven therapy options to select the right patient for the right treatment at the right time. In this webinar Prof Tony Mok,Chinese University of Hong Kong, and Prof Keith Kerr, University of Aberdeen, Scotland, .provide updates on treatment options in NSCLC, along with the oncology and pathology perspectives on molecular testing challenges and considerations in the clinical decision-making for lung cancer patients.

NTRK Rearrangements in Oncology: Diagnostic Strategies and Therapeutic Relevance

November 21, 2019, 61 minutter
 Dr. Eric Konnick, University of Seattle, Washington, US. In this webinar, Dr. Konnick will discuss the biology, background and rationale for targeting TRK fusions. You will learn about the clinical evidence for TRK inhibitors and issues implementing pan-tumor assays, specifically pan-TRK assays.

EGFR Mutation in Lung Carcinoma

Apr 29 2019, 10 minutter
EGFR Mutation in Lung Carcinoma presented by Dr. Philippe Taniere, MD, PhD, University Hospital Birmingham, Birmingham, UK